MetaVia, Inc. (MTVA)
1.01
-0.06
(-5.61%)
USD |
NASDAQ |
Nov 20, 16:00
1.00
-0.01
(-0.99%)
After-Hours: 20:00
MetaVia Total Assets (Quarterly) : 9.554M for Sept. 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 9.554M |
| June 30, 2026 | 13.27M |
| March 31, 2026 | 14.39M |
| December 31, 2025 | 69.12M |
| September 30, 2025 | 14.76M |
| June 30, 2025 | 18.46M |
| March 31, 2025 | 12.13M |
| December 31, 2024 | 16.26M |
| September 30, 2024 | 22.15M |
| June 30, 2024 | 28.75M |
| March 31, 2024 | 17.02M |
| December 31, 2023 | 22.78M |
| September 30, 2023 | 26.42M |
| June 30, 2023 | 29.18M |
| March 31, 2023 | 31.49M |
| December 31, 2022 | 33.53M |
| September 30, 2022 | 7.557M |
| June 30, 2022 | 10.08M |
| March 31, 2022 | 13.46M |
| December 31, 2021 | 16.80M |
| September 30, 2021 | 8.077M |
| June 30, 2021 | 10.72M |
| Date | Value |
|---|---|
| March 31, 2021 | 14.16M |
| December 31, 2020 | 10.97M |
| September 30, 2020 | 13.20M |
| June 30, 2020 | 15.55M |
| March 31, 2020 | 11.54M |
| December 31, 2019 | 14.47M |
| September 30, 2019 | 2.048M |
| June 30, 2019 | 4.014M |
| March 31, 2019 | 6.158M |
| December 31, 2018 | 19.69M |
| September 30, 2018 | 24.87M |
| June 30, 2018 | 28.81M |
| March 31, 2018 | 34.84M |
| December 31, 2017 | 19.02M |
| September 30, 2017 | 26.21M |
| June 30, 2017 | 23.00M |
| March 31, 2017 | 29.84M |
| December 31, 2016 | 24.75M |
| September 30, 2016 | 28.92M |
| June 30, 2016 | 6.726M |
| March 31, 2016 | 2.637M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.794B |
| Alnylam Pharmaceuticals, Inc. | 7.995B |
| Anika Therapeutics, Inc. | 189.60M |
| Savara, Inc. | 155.93M |
| Arrowhead Pharmaceuticals, Inc. | 1.810B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 7.143M |
| Shareholders Equity (Quarterly) | 2.411M |
| Debt to Equity Ratio | 0.0664 |
| Current Ratio | 1.284 |
| Net Debt Paydown Yield | -0.12% |